Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use

Annals of Pharmacotherapy

Volumn 43, Issue 12, 2009, Pages 1948-1955

  Mendes, Carlos A C ^a   Cordeiro, José A ^b   Burdmann, Emmanuel A ^a  

^a HOSPITAL DE BASE   (Brazil)

^b São José do Rio Preto Medical School   (Brazil)

Author keywords

Acute kidney injury; Nephrotoxicity; Polymyxin B

Indexed keywords

CREATININE; FUROSEMIDE; POLYMYXIN B; VASOACTIVE AGENT;

ABDOMEN; ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BACTERIUM ISOLATION; BLOOD; CATHETER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE COURSE; DRUG USE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CREATININE; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY FAILURE, ACUTE; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMYXIN B; PREVALENCE; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 72249099839     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M277     Document Type: Article

References (43)

1. Falagas EM, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-1341 DOI 10.1086/429323
2. Koike M, Iida K, Matsuo T. Electron microscopy studies on the mode of action of polymyxin. J Bacteriol 1969;97:448-452
3. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999;43:1317-1323
4. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977;46:723-763 DOI 10.1146/annurev.bi.46.070177. 003451
5. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006;12:315-321 DOI 10.1111/j.1469-0691.2005. 01351.x
6. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128-132 DOI 10.1093/jac/dki175
7. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michaloupoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005;5:24. DOI 10.1186/1471-2334-5-24 (Pubitemid 41363802)
8. Horton J, Pankey GA. Polymyxin B, colistin, and sodium colistimethate. Med Clin North Am 1982;66:135-142
9. Archibald L, Phillips L, Monnet D, McGowan JE, Tenove F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the Intensive Care Unit. Clin Infect Dis 1997;24:211-215 (Pubitemid 27081545)
10. Levin AS, Mendes CM, Sinto SI, et al. An outbreak of multiresistant Acinetobacter baumanii in a university hospital in São Paulo, Brazil. Infect Control Hosp Epidemiol 1996;17:366-368
11. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-967 DOI 10.1345/aph.18426
12. Pedersen MF, Pedersen JF, Adsen PO. A clinical and experimental comparative study of sodium colistimethate and polymyxin B sulfate. Invest Urol 1971;9:234-237
13. Santos WJ, Zanetta DM, Pires AC, Lobo SM, Lima EQ, Burdmann EA. Patients with ischaemic, mixed and nephrotoxic acute tubular necrosis in the intensive care unit - a homogeneous population (abstract)? Crit Care 2006;10:R68. DOI 10.1186/cc4904
14. Greenacre MJ, ed. Theory and applications of correspondence analysis. London: AC Press, 1984.
15. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies (abstract). Crit Care 2006;10: R27. DOI 10.1186/cc3995
16. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007;5:811-821 DOI 10.1586/14787210.5.5.811
17. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566-569 DOI 10.1093/jac/dkh369 (Pubitemid 39177490)
18. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-2662 DOI 10.1128/AAC.47.8.2659-2662.2003
19. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006;40:1939-1945 Epub 3 Oct 2006. DOI 10.1345/aph.1H353
20. Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007;30:315-319 DOI 10.1016/j.ijantimicag.2007.05.017
21. Pastewski AA, Caruso P, Parris AR, et al. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann Pharmacother 2008;42: 1177-1187 Epub 29 Jul 2008. DOI 10.1345/aph.1K346
22. Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-1011 DOI 10.1086/514732 (Pubitemid 29203530)
23. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-868
24. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-121. DOI 10.1111/j.1469-0691.2004.01043.x
25. Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP,Walshaw MJ. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 1998;12:592-594 DOI 10.1183/09031936.98.12030592 (Pubitemid 28420136)
26. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-1118 DOI 10.1086/374337
27. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Int Care Med 2005;31:1058-65. DOI 10.1007/s00134-005-2691- 4
28. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417-420 DOI 10.1093/jac/dkm509
29. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin (abstract). BMC Infect Dis 2005;5:1. DOI 10.1186/1471-2334-5-1
30. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005;26:504-507 DOI 10.1016/j.ijantimicag.2005.09.004 (Pubitemid 41635502)
31. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49:3136-3146 DOI 10.1128/AAC.49.8.3136-3146.2005 (Pubitemid 41060551)
32. Kallel H, Bahloul M, Hergafi L, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006;28:366-369 DOI 10.1016/j.ijantimicag.2006.07.008 (Pubitemid 44403003)
33. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007;51:905-911 DOI 10.1128/AAC.01015-06
34. Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect 2008;56:185-190 DOI 10.1016/j.jinf.2008.01.003
35. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/ sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008;61:1369-1375 DOI 10.1093/jac/dkn128
36. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007;33:1162-1167 DOI 10.1007/s00134-007-0675-2 (Pubitemid 47036903)
37. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12. DOI 10.1186/cc2872
38. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury (abstract). Crit Care 2007;11:R31. DOI 10.1186/cc5713
39. Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med 1962;266:759-762
40. Product information. Polymyxin B sulfate sterile, 500,000 units. Bedford, OH: Bedford Laboratories, July 2009.
41. Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004;286:C913-22. DOI 10.1152/ajpcell.00437.2003
42. Teng CB, Koh PT, Lye DC, Ang BS. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug- resistant Gram-negative bacteria. Int J Antimicrob Agents 2008; 31:80-82 DOI 10.1016/j.ijantimicag.2007.08.004
43. Leblanc M, Kellum JA, Gibney RT, Lieberthal W, Tumlin J, Mehta R. Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care 2005;11:533-536 (Pubitemid 41697323)